



**BIOSENSORS
INTERNATIONAL**

NEWS RELEASE

Biosensors Announces Second Quarter and Half Year Financial Results of Fiscal Year 2008

Singapore 12 November 2007 - Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP) today announced financial results for the second fiscal quarter ("2Q FY08") and the fiscal six-months ended September 30, 2007.

Product revenues were US\$9.0 million for 2Q FY08 compared to US\$8.2 million for the same period in the prior year, an increase of 10%. For the six months ended September 30, 2007, product revenues were US\$18.3 million compared to US\$16.1 million for the prior year period, an increase of 14%. Beginning with the quarter under review, the Company has classified sales of its traditional interventional cardiology products and drug-eluting stents into a single product segment known as interventional cardiology products to align with internal management reporting. For the quarter ending September 30, 2007, revenue for this segment was US\$6.0 million compared to US\$5.6 million in the same period in the prior year, an increase of 8%. For the six months ended September 30, 2007, interventional cardiology product revenues were US\$12.7 million, representing a 15% increase from US\$11.0 million in same period in the prior year. The increases in interventional cardiology revenues were due to growth in sales of bare-metal stents in the Japanese market along with increased OEM sales in Asia. Sales of current-generation drug-eluting stents, however, decreased as the focus was shifted from the current generation drug-eluting stent to the Company's future drug-eluting stent, BioMatrix®, currently awaiting regulatory approvals. The Company also recorded additional reserve for potential product returns.

Licensing revenue in 2Q FY08 was not material, consistent with 2Q FY07, and consistent with management's expectations as licensing revenue is non-recurring in nature. Gross margins for 2Q FY08 were 34% compared to 42% in the prior period's quarter and 37% for the six months ended September 30, 2007 compared to 44% for the same period last fiscal year. Gross margins decreased for both the interventional cardiology and critical care product lines. For the interventional cardiology product line, the decrease was a result of higher provisions made for inventory obsolescence and potential product returns for current-generation drug-eluting stents, partially offset by continuing margin improvement for the traditional interventional products. The decrease in margins for the critical care product line relates to increased costs associated with the restructuring of the Company's manufacturing activities in Asia for this product line. The restructuring is expected to be completed during the next quarter.

Mr. Yoh-Chie Lu, Chairman and CEO of Biosensors said, "While we continue to plan for commercialization following CE Mark approval of our BioMatrix® drug-eluting stent in Europe and some Asian countries, we have begun to implement new strategies that focus on building strong bases of business in markets such as China, Indonesia and other fast-growing Asian countries. We believe that execution in these areas will allow us to create a large, growing and profitable enterprise, well before we complete the regulatory requirements necessary to launch our drug-eluting stent products in the US. During this quarter, we completed three significant transactions which position us to accelerate penetration of some of these fast-growing Asian drug-eluting stent markets. First, we completed the acquisition of 50% of JW Medical Systems ("JWMS"), one of the top three providers of drug-eluting stents in the China market in a little over a year after commercialization of its Excel drug-eluting stent. According to market data, the China market exceeded US\$185 million in revenue for the first six months of 2007. Analysts predict that accelerated growth will continue in the China market, with anticipated Chinese drug-eluting stent sales exceeding the Japanese market within two years."

"We estimate that JWMS' revenues for the next twelve months will be in the range of US\$35 to US \$40 million with profit before tax of approximately 40%. Under current International Financial Reporting Standards ("IFRS") reporting requirements, we will proportionately consolidate the financial results of JWMS with Biosensors, which we expect to be accretive to our operating results." Mr Lu said.

"Second, the Company announced the acquisition of certain businesses from a leading medical product distributor in Indonesia. Through this acquisition the Company established a direct sales presence for its interventional cardiology and critical care products in Indonesia. Lastly, the Company signed a Memorandum of Understanding in August 2007 with PT Kimia Farma, a state-owned healthcare company in Indonesia, to distribute the Company's current coronary products to more than 390 government hospitals in Indonesia and to eventually localize the manufacturing of the Company's bare-metal stents and accessory products to serve that market." Mr Lu added.

Mr Lu further commented, “Our strategy to establish a strong presence in these countries will enable us to move our emerging technologies more efficiently into these and other international geographic areas after we receive regulatory approvals. After all, the market size for drug-eluting stents in Asia and Europe account for half of the global drug-eluting stent market. We remain optimistic that as our long-term strategies are implemented our operating results will improve.”

For the quarter ended 30 September 2007, research and development (“R&D”) expenses, which include costs for new product development and testing, clinical trials, patent registration and regulatory approvals, were US\$5.9 million compared to US\$5.3 million in the prior year’s corresponding period. For the six-months ended September 30, 2007, R&D expenses were US\$13.1 million compared to US\$10.4 million in prior year’s corresponding period. This increase relates primarily to increased expenditures for clinical trials and consulting services relating to regulatory approvals.

Sales and marketing expenses were US\$4.9 million in 2Q FY08 compared to US\$3.3 million in the prior year’s corresponding quarter and were US\$8.4 million in this fiscal half-year compared to US\$5.8 million in fiscal half-year in FY07. The increases were due mainly to expenses incurred to enhance the sales and marketing support functions and increased allowances made for doubtful trade debts.

General and administrative expenses were US\$4.1 million in 2Q FY08 compared to US\$4.5 million in the prior year’s corresponding quarter and totaled US\$8.6 million in the half year compared to US\$8.4 million in the last fiscal half-year.

For the quarter ended 30 September 2007, the Group reported a net loss of US\$11.0 million or 1.19 US cents loss per basic and diluted share, compared to a net loss of US\$9.2 million or 1.01 US cent loss per basic and diluted share for the prior year’s corresponding period. For the six month period, the Group reported a net loss of US\$3.0 million or 0.33 US cent loss per basic and diluted share compared to a net loss of US\$15.9 million or 1.75 US cent loss per basic and diluted share for the prior six month period. Included in the net loss per share for the quarter ended 30 September 2007 is an additional provision for income taxes of approximately US\$1.1 million to increase the Company’s deferred income tax liabilities for potential future income tax expense.

Media Contact

Biosensors International Group
Mr. Loh Chee Mun
Senior Vice President
Tel: (65) 6213 5712
Email: cm.loh@biosensors.com

Media Relations / Investor Relations Firm

United States
Allen & Caron Inc.
Mr. Matt Clawson
Executive Vice President, Investor Relations
Tel: (1) 949 474 4300
Email: matt@allencaron.com

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenotic drug. It is pursuing three separate drug-eluting stent programs, BioMatrix®, Axxion™, and BioMatrix® Freedom™, a polymer-free drug-eluting stent, and has licensed aspects of its drug-eluting stent technology to four companies.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.

###